Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
NCT ID: NCT00340080
Last Updated: 2010-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1806 participants
INTERVENTIONAL
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
NCT00435838
Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment
NCT01346878
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
NCT00000891
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
NCT01328041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abacavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects are Abacavir-naive (subjects can be antiretroviral therapy (ART)-naive or experienced).
* All subjects must have a clinical need for treatment with Abacavir (ABC) or an ABC-containing product that precedes the decision to participate in the study.
* If subjects are therapy naive they must meet the criteria for commencing HAART according to local guidelines.
* ABC and ABC-containing products are not recommended during pregnancy. A female is eligible to enter and participate in the study if she is of:
1. Non-child-bearing potential: women who are surgically sterile or post-menopausal, the latter indicated by history of no menses for a minimum of 1 year from the date of the screening visit.
2. Child-bearing potential: women who provide a negative pregnancy test (beta-human chorionic gonadotrophin; beta-HCG) at Screening and who agree to one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the approved product label and the instructions of a physician, during the study period and through epicutaneous patch testing where appropriate):
* Complete abstinence from intercourse from 4 weeks prior to administration of the ABC-containing compound, throughout the study, and for at least 4 weeks after discontinuation of ABC or ABC-containing product.
* Double barrier method (e.g., male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraceptives will not be considered sufficient forms of contraception for this study.
* Any intrauterine device with published data showing that the expected failure rate is \<1% per year.
* Sterilisation (male partner of female subject).
Exclusion Criteria
* Satisfies any contraindications or restrictions to ABC therapy as listed in the product labels. Treatment with ABC must be in line with the recommendations of the product label.
* The subject or any of their healthcare providers is aware of the subjects HLA type.
* Has undergone an allogeneic bone marrow transplant.
* Has an active or acute CDC Clinical Category C event at screening. Treatment for the acute event must have been completed at least 30 days prior to Screening.
* Current severe illness, including liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.
* Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study.
* Pregnant women or women who are breastfeeding.
* Any immunisation within 30 days prior to Day 1.
* Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.
* Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to Screening, or has an anticipated need for these agents within the study period.
* Subject is enrolled in one or more investigational drug/vaccine protocols.
* In France, an eligible subject is neither affiliated with nor a beneficiary of a social security category.
* A subject will not be eligible for progression to Baseline (Day 1) if any of the following criteria apply:
* A positive result for HLA-B\*5701 in those subjects randomised to the genetic screening arm.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MB BS MRCP FFPM
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Miami, Queensland, Australia
GSK Investigational Site
Graz, , Austria
GSK Investigational Site
Innsbruck, , Austria
GSK Investigational Site
Linz, , Austria
GSK Investigational Site
Salzburg, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Bruges, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Liège, , Belgium
GSK Investigational Site
Aix-en-Provence, , France
GSK Investigational Site
Amiens, , France
GSK Investigational Site
Angers, , France
GSK Investigational Site
Annecy, , France
GSK Investigational Site
Avignon, , France
GSK Investigational Site
Besançon, , France
GSK Investigational Site
Bobigny, , France
GSK Investigational Site
Bondy, , France
GSK Investigational Site
Bordeaux, , France
GSK Investigational Site
Bordeaux, , France
GSK Investigational Site
Caen, , France
GSK Investigational Site
Cannes, , France
GSK Investigational Site
Clermont-Ferrand, , France
GSK Investigational Site
Corbeil-Essonnes, , France
GSK Investigational Site
Créteil, , France
GSK Investigational Site
Dijon, , France
GSK Investigational Site
Fréjus, , France
GSK Investigational Site
Grenoble, , France
GSK Investigational Site
La Roche-sur-Yon, , France
GSK Investigational Site
La Rochelle, , France
GSK Investigational Site
Le Kremlin-Bicêtre, , France
GSK Investigational Site
Levallois-Perret, , France
GSK Investigational Site
Lyon, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Metz, , France
GSK Investigational Site
Montpellier, , France
GSK Investigational Site
Mulhouse, , France
GSK Investigational Site
Nantes, , France
GSK Investigational Site
Nice, , France
GSK Investigational Site
Niort, , France
GSK Investigational Site
Nîmes, , France
GSK Investigational Site
Orléans, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Perpignan, , France
GSK Investigational Site
Poitiers, , France
GSK Investigational Site
Quimper, , France
GSK Investigational Site
Reims, , France
GSK Investigational Site
Rennes, , France
GSK Investigational Site
Rouen, , France
GSK Investigational Site
Saint-Brieuc, , France
GSK Investigational Site
Saint-Denis, , France
GSK Investigational Site
Saint-Etienne, , France
GSK Investigational Site
Saint-Germain-en-Laye, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Toulouse, , France
GSK Investigational Site
Tourcoing, , France
GSK Investigational Site
Tours, , France
GSK Investigational Site
Troyes, , France
GSK Investigational Site
Valence, , France
GSK Investigational Site
Valenciennes, , France
GSK Investigational Site
Villejuif, , France
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Stuttgart, Baden-Wurttemberg, Germany
GSK Investigational Site
Erlangen, Bavaria, Germany
GSK Investigational Site
Fürth, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Würzburg, Bavaria, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Osnabrück, Lower Saxony, Germany
GSK Investigational Site
Bochum, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Dortmund, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Münster, North Rhine-Westphalia, Germany
GSK Investigational Site
Münster, North Rhine-Westphalia, Germany
GSK Investigational Site
Mainz, Rhineland-Palatinate, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Magdeburg, Saxony-Anhalt, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Kfar Saba, , Israel
GSK Investigational Site
Ramat Gan, , Israel
GSK Investigational Site
Rehovot, , Israel
GSK Investigational Site
Tel Aviv, , Israel
GSK Investigational Site
Bari, Apulia, Italy
GSK Investigational Site
Catanzaro, Calabria, Italy
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Salerno, Campania, Italy
GSK Investigational Site
Bologna, Emilia-Romagna, Italy
GSK Investigational Site
Bologna, Emilia-Romagna, Italy
GSK Investigational Site
Ferrara, Emilia-Romagna, Italy
GSK Investigational Site
Piacenza, Emilia-Romagna, Italy
GSK Investigational Site
Rimini, Emilia-Romagna, Italy
GSK Investigational Site
Latina, Lazio, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Sanremo (im), Liguria, Italy
GSK Investigational Site
Bergamo, Lombardy, Italy
GSK Investigational Site
Brescia, Lombardy, Italy
GSK Investigational Site
Busto Arsizio (va), Lombardy, Italy
GSK Investigational Site
Cuggiono (mi), Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Asti, Piedmont, Italy
GSK Investigational Site
Pallanza (Verbania), Piedmont, Italy
GSK Investigational Site
Turin, Piedmont, Italy
GSK Investigational Site
Cagliari, Sardinia, Italy
GSK Investigational Site
Sassari, Sardinia, Italy
GSK Investigational Site
Catania, Sicily, Italy
GSK Investigational Site
Torrette Di Ancona (an), The Marches, Italy
GSK Investigational Site
Bolzano, Trentino-Alto Adige, Italy
GSK Investigational Site
Grosseto, Tuscany, Italy
GSK Investigational Site
Padua, Veneto, Italy
GSK Investigational Site
Treviso, Veneto, Italy
GSK Investigational Site
Vicenza, Veneto, Italy
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Alkmaar, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Arnhem, , Netherlands
GSK Investigational Site
Enschede, , Netherlands
GSK Investigational Site
Flushing, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Nijmegen, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
Tilburg, , Netherlands
GSK Investigational Site
Zwolle, , Netherlands
GSK Investigational Site
Fredrikstad, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Chorzów, , Poland
GSK Investigational Site
Szczecin, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Almada, , Portugal
GSK Investigational Site
Amadora, , Portugal
GSK Investigational Site
Aveiro, , Portugal
GSK Investigational Site
Cascais, , Portugal
GSK Investigational Site
Lisbon, , Portugal
GSK Investigational Site
Monte Funchal, , Portugal
GSK Investigational Site
Ponta Delgada, , Portugal
GSK Investigational Site
Porto, , Portugal
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Constanța, , Romania
GSK Investigational Site
Iași, , Romania
GSK Investigational Site
Barnaul, , Russia
GSK Investigational Site
Belgorod, , Russia
GSK Investigational Site
Krasnodar, , Russia
GSK Investigational Site
Lipetsk, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Murmansk, , Russia
GSK Investigational Site
N.Novgorod, , Russia
GSK Investigational Site
Oryol, , Russia
GSK Investigational Site
Perm, , Russia
GSK Investigational Site
Ryazan, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
Saratov, , Russia
GSK Investigational Site
Smolensk, , Russia
GSK Investigational Site
Volgograd, , Russia
GSK Investigational Site
Ljubljana, , Slovenia
GSK Investigational Site
A Coruña, , Spain
GSK Investigational Site
Alcalá de Henares, , Spain
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Baracaldo/Vizcaya, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Bilbao, , Spain
GSK Investigational Site
Calella, , Spain
GSK Investigational Site
Córdoba, , Spain
GSK Investigational Site
Elche (Alicante), , Spain
GSK Investigational Site
Granada, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Marid, , Spain
GSK Investigational Site
Mataró, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Oviedo, , Spain
GSK Investigational Site
Reus, , Spain
GSK Investigational Site
San Sebastián, , Spain
GSK Investigational Site
Santander, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Tarragona, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Vigo ( Pontevedra), , Spain
GSK Investigational Site
Vitoria-Gasteiz, , Spain
GSK Investigational Site
Basel, , Switzerland
GSK Investigational Site
Bruderholz, , Switzerland
GSK Investigational Site
La Chaux-de-Fonds, , Switzerland
GSK Investigational Site
Lausanne, , Switzerland
GSK Investigational Site
Lausanne, , Switzerland
GSK Investigational Site
Lugano, , Switzerland
GSK Investigational Site
Sankt Gallen, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
GSK Investigational Site
Derby, Derbyshire, United Kingdom
GSK Investigational Site
Manchester, Lancashire, United Kingdom
GSK Investigational Site
Woolwich, London, London, United Kingdom
GSK Investigational Site
Nottingham, Nottinghamshire, United Kingdom
GSK Investigational Site
Stoke-on-Trent, Staffordshire, United Kingdom
GSK Investigational Site
Belfast, , United Kingdom
GSK Investigational Site
Birmingham, , United Kingdom
GSK Investigational Site
Coventry, , United Kingdom
GSK Investigational Site
Dudley, Birmingham, , United Kingdom
GSK Investigational Site
East Yorkshire, , United Kingdom
GSK Investigational Site
Farnworth, Bolton, , United Kingdom
GSK Investigational Site
Glasgow, , United Kingdom
GSK Investigational Site
Gloucester, , United Kingdom
GSK Investigational Site
Leicester, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Middlesbrough, , United Kingdom
GSK Investigational Site
Plaistow, London, , United Kingdom
GSK Investigational Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PREDICT-1
Identifier Type: -
Identifier Source: secondary_id
CNA106030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.